Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat with/without ATRA in Advanced Myeloid Malignancies
NCT02842827Phase 2Completed
- Sponsor
- Imago BioSciences, Inc.
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bomedemstat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (8 cohorts), sponsored by Imago BioSciences, Inc. Primary endpoints: Number of Participants Who Experienced an Adverse Event (AE) up to 24 months, Number of Participants Who Experienced a Serious Adverse Event (SAE) up to 24 months and 6 more. Started Oct 2016; status: completed.
02
Drugs
bomedemstat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02842827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842827.